Performance evaluation of neuroprotective therapy of experimental allergic encephalomyelit is under basic the rapy with solumedrol
A comparative analysis of the neuroprotective effect of Citicoline, Neurovitan and lipoic acid on the model of experimental equivalent of multiple sclerosis in rats under baseline hormone therapy with methylprednisolone (Solu-Medrol) was conducted. Experimental allergic encephalomyelitis (EAE) was developed on 9-11 days after inoculation of encephalitogenic mixture in 92% of the rats in the control group. In most rodent of control group prevailed severe and prolonged during course of EAE (mean cumulative index of 27,2; mean duration of illness of 16,4 days). Injection of Solu-Medrol (SM, 3,4 mg/kg intravenously over a week) prevented the development of EAE in 20% of animals and from infected rodents in 2-3 times (compared with control) reduced the severity and duration of neurological disorders. Course application of Neurovitan (25 mg/kg) and Berlitione (50 mg/kg) during therapy with Solu-Medrol prevented the development of EAE in 25% of the animals, did not change significantly compared with the SM group studied the characteristics of the experimental equivalent of multiple sclerosis. The animals treated with Citicoline (500 mg/kg) in a course of hormone therapy SM, EAE developed only after completion of drug injection (on 19- 20 day), leaking momentarily (average 5 days) and mild (average cumulative index 6.6). High efficiency of Citicoline with EAE mediated the weakening of the activity of phospholipase A2 activation and neuronal mitochondrial cytochrome oxidase on the one hand, and the other - the inhibition of glutamate-induced apoptosis.